Abstract
Background:
Extended low serum thyrotropin (TSH) levels may increase the risk of cardiovascular events in patients with hyperthyroidism.Objectives:
This study aimed to compare the time spent with sustained normal TSH concentration following short- and long-term methimazole treatment.Methods:
A total of 258 patients with Graves’ hyperthyroidism completed 18 - 24 months of methimazole therapy and were randomized to discontinue treatment (n = 128, short-term group) or continue an additional 36 - 102 months of methimazole therapy (n = 130, long-term group). Clinical and laboratory evaluations were performed every 6 months for 132 months after randomization.Results:
There was no difference in serum-free thyroxine, triiodothyronine, and TSH concentrations between the 2 groups at the time of randomization. Of 128 patients in the short-term group, 5 left in follow-up, 2 became hypothyroid, 67 (54%) had a relapse of hyperthyroidism, and only 54 (44%) were euthyroid at the end of the study. Among 130 patients on the long-term methimazole therapy, 4 were left in follow-up, 24 developed hyperthyroidism, 4 developed hypothyroidism, and 98 (78%) were euthyroid 132 months post-randomization. Total time spent on euthyroidism was 90.4% ± 8.1% of the study period in the short-term and 95.8% ± 7.0% in the long-term treatment groups (P < 0.001). The lowest time spent in euthyroidism (74.6% ± 6.4% of the study period) belonged to 29 (24%) patients in the short-term group under levothyroxine therapy because of fluctuation in serum TSH. Patients in both groups with hyperthyroidism relapse who chose methimazole therapy spent >90% of the study time in euthyroidism.Conclusions:
In patients with Graves' hyperthyroidism, sustained normal serum TSH levels were more common in the long term as compared to the short-term methimazole treatment.Keywords
Euthyroidism Methimazole Therapy Thionamide TSH Receptor Antibody
1. Background
Graves’ disease is the most common cause of thyrotoxicosis. This autoimmune disease is caused by thyrotropin (TSH) receptor antibodies (TRAb) stimulating the TSH receptor of the thyroid cell membrane. There are controversies in choosing the appropriate treatment for Graves’ disease. Radioactive iodine, antithyroid drugs (ATDs), and surgery are therapeutic modalities for diffuse toxic goiter. All these approaches have advantages and disadvantages, and none of them can render all patients with Graves’ disease permanently euthyroid (1).
Thianomide antithyroid agents have been a mainstay in treating patients with Graves’ hyperthyroidism for over 75 years (2); however, the rate of relapse is approximately 50% following the cessation of 12 - 18 months of treatment. Recent reports indicate that long-term ATD (LT-ATD) therapy increases the remission rate up to 85% following the discontinuation of such treatment (3-5).
The main objective of hyperthyroidism treatment is to re-establish normal thyroid physiology (2). However, consideration of cardiovascular safety is of utmost importance when treating hyperthyroidism. An increase in all-cause mortality in patients with hyperthyroidism (6) raised the risk of mortality and substantial cardiovascular morbidity in patients with uncorrected hyperthyroidism (7). Moreover, the association of longer-suppressed serum TSH with cardiovascular outcomes in treated and untreated hyperthyroid patients (8) indicated that euthyroidism should be induced rapidly and sustained throughout the management of hyperthyroid patients (7, 9).
2. Objectives
The purpose of this study was to compare “the time spent in sustained euthyroidism” following short-term methimazole (ST-MMI) and long-term methimazole (LT-MMI) treatment in patients with Graves’ disease.
3. Methods
3.1. Study Design
In this study, we explored the follow-up data of one of the randomized control trials of towards outstanding hyperthyroid care induced by antithyroid drugs (TOHID) studies. TOHIDs registered in the Iranian Registry of Clinical Trials [https://irct.behdasht.gov.ir/trial/5143] are a combination of observational studies and clinical trials for evaluating treatment modalities in patients with hyperthyroidism (10, 11) in an iodine-sufficient region (12). The present clinical trial compared remission rates following the discontinuation of ST-MMI and LT-MMI treatments. Details of the trial were reported before (5). Briefly, 302 patients with an untreated first episode of Graves' hyperthyroidism were treated with MMI for a median of 19 months, and 258 of them were randomized to discontinue MMI (short-term group, n = 128) or continue methimazole for 36 - 120 months (long-term group, n = 130). Total time on methimazole was 60 - 120 months in the long-term group (mean: 95 ± 32 months). All patients were followed 132 months after randomization (Figute 1).
Study enrollment and follow-up for the recurrence of hyperthyroidism. MMI: methimazole.
3.2. Methimazole Therapy
After the daily administration of 20 - 30 mg MMI for one month, it was titrated to keep free thyroxine (FT4) between 9 - 23 pmol/L and TSH<5.09 mIU/L. Patients in the long-term group continued an additional course of methimazole after randomization, with further titration as needed to meet therapeutic goals.
3.3. Procedures
Demographic data were obtained, and goiter size was estimated with palpation at entry. Patients were followed every 6 months after randomization and at each visit. Serum concentrations of FT4, triiodothyronine (T3), TSH, and TRAb were measured by commercial kits. Inter-assay and intra-assay coefficients of variation were <6.1% and <9.1% for all measurements, respectively.
3.4. Endpoints
The primary endpoints were the percent of time spent in euthyroidism, hypothyroidism, and hyperthyroidism, as well as sustained euthyroidism from the day of randomization to the end of follow-up. Goiter was assessed by palpation according to the World Health Organization criteria (12).
3.5. Definitions
Overt hypothyroidism was defined as FT4<9 pmol/L and TSH>5.06 mIU/L for people in Tehran, Iran (13). Subclinical hypothyroidism was defined as TSH>5.06 mIU/L with normal serum FT4 and T3 concentrations. Hyperthyroidism was defined as TSH<0.4 mIU/L (reference range: 0.4-5.06 mIU/L) with FT4>23 pmol/L (reference range: 9 - 23 pmol/L) and/or T3>200 ng/dL (reference range: 75 - 200 ng/dL). Moreover, subclinical hyperthyroidism was defined as TSH<0.4 mIU/L with serum FT4 and T3 within the reference ranges.
3.6. Statistical Analysis
Two hundred sixty patients were needed for a small-medium effect size of 0.40, with 80% power and 5% significance, allowing for 30% attrition. Two hundred forty-two patients completed the study. The post-hoc test power for this number of patients was calculated with the same effect of 87%.
All analyses were performed using IBM SPSS statistical software version 25 (SPSS Inc., Chicago, IL, USA). Quantitative variables were summarized using mean and standard deviation. Qualitative variables were reported as frequency and percentage. Variables were compared between two groups with Student t, Mann-Whitney, chi-square, or Fisher’s exact tests. Time spent on various thyroid function statuses for each patient was calculated from the date of randomization when all patients in both groups were euthyroid. Percent of time that serum TSH, FT4, and T3 remained in various thyroid function categories, according to the definitions mentioned above, was calculated. The event date for thyroid status cases was described as the middle time between the date of the follow-up visit and the diagnosis. Two-tailed P-value<0.05 was considered significant.
4. Results
4.1. Patient Characteristics
A total of 258 patients completed 19 ± 3 months of methimazole treatment before randomization. All patients had normal serum FT4, T3, and TSH concentrations at randomization (Table 1).
Patient Characteristics by Study Arms at the Time of Randomization a
| Variables | Short-term Methimazole (n = 128) | Long-term Methimazole (n = 130) |
|---|---|---|
| Age (y) | 39.7 ± 12.6 | 42.8 ± 13.3 |
| Female | 94 (73) | 104 (80) |
| Goiter grade | ||
| 0 or 1 | 61 (48) | 96 (74) |
| 2 | 67 (52) | 34 (26) |
| Current smoking | 20 (16) | 17 (13) |
| FT4 (pmol/L) | 16.9 ± 3.2 | 16.7 ± 2.5 |
| T3 (ng/dL) | 130 ± 21 | 133 ± 19 |
| TSH (mIU/L) | 1.7 ± 1.2 | 2.1 ± 1.8 |
| TRAb (IU/L) | 1.0 ± 0.7 | 1.2 ± 0.9 |
Among 258 randomized patients, 130 were assigned to longer-term therapy, and 128 discontinued methimazole (short-term group). Of these 128 patients, 5 were left in follow-up. By the end of 132 months post-randomization, 67 (54%) patients had a relapse of hyperthyroidism, and 2 patients developed hypothyroidism. Therefore, only 54 (44%) cases were euthyroid at the end of the study without receiving treatment for thyroid dysfunction. Out of 130 patients on long-term methimazole therapy, 4 were left to follow up, 24 developed hyperthyroidism, 4 developed hypothyroidism, and 98 (78%) were euthyroid at 132 months post-randomization (Table 2).
Thyroid Function Status During Post-Randomization 132 Months of Follow-up a
| Variables | Short-term Methimazole (n = 128) | Long-term Methimazole (n = 130) |
|---|---|---|
| Left follow-up | 5 | 4 |
| Thyroid status outcome | ||
| Relapse of hyperthyroidism | 67 (54) | 24 (19) |
| Spontaneous hypothyroidism | 2 (2) | 4 (3) |
| Euthyroidism | 54 (44) | 98 (78) |
| Thyroid status at the end of the study | ||
| Euthyroid | 74 (60.1) | 98 (77.7) |
| Hypothyroid on levothyroxine | 29 (23.6) | 7 (5.6) |
| Hyperthyroid on methimazole | 20 (16.3) | 21 (16.7) |
4.2. Thyroid Status at the End of the Study
Of patients who had a hyperthyroidism relapse during the study period, 46 and 2 chose radioactive iodine, while 21 and 22 patients chose long-term methimazole treatment in the short- and long-term groups, respectively. We observed that 28 of 48 patients treated with radioactive iodine became hypothyroid, and 20 became euthyroid. Among 43 patients on long-term methimazole, 41 were euthyroid, and 2 were hypothyroid by the end of the study (Figure 1).
4.3. Time Spent on Various Thyroid Status
Patients in the short- and long-term methimazole groups spent 90.4% ± 8.1% and 95.8% ± 7.0% of the study period in euthyroidism, respectively (P < 0.001). The time spent in euthyroidism was not significantly different between the two groups: 94.5 ± 5.1 vs. 95.8 ± 7.0 months, respectively. The lowest time spent in euthyroidism (74.6 ± 6.4 months) belonged to 29 (24%) of the patients in the short-term group who were on levothyroxine treatment because of hypothyroidism. Patients in both groups who had a recurrence of hyperthyroidism and chose methimazole therapy spent >90% of their study time in euthyroidism (Table 3).
Percent of Time Spent in Various Thyroid Function Statuses in Patients with Graves Hyperthyroidism Treated with Short- and Long-Term Methimazole a
| Methimazole Treatment Group | Percent of Time Spent in | ||
|---|---|---|---|
| Euthyroidism | Subclinical Hyperthyroidism | Subclinical Hypothyroidism | |
| Short-term (n = 123) | 90.4 ± 8.2 b | 6.7 ± 5.8 | 2.9 ± 4.0 |
| Euthyroid (74) | 94.5 ± 5.1 | 3.5 ± 3.9 | 2.0 ± 3.6 |
| Hypothyroid on levothyroxine (29) | 79.6 ± 6.4 b | 13.5 ± 4.9 | 6.9 ± 3.4 b |
| Hyperthyroid on methimazole (20) | 91.8 ± 5.2 | 7.8 ± 5.4 | 0.4 ± 0.1 |
| Long-term (n = 126) | 95.0 ± 7.1 | 4.8 ± 7.2 | 0.2 ± 0.9 |
| Euthyroid (98) | 95.8 ± 7.0 | 4.1 ± 6.6 | 0.1 ± 0.8 |
| Hypothyroid on levothyroxine (7) | 92.3 ± 10.8 | 7.7 ± 10.8 | 0 |
| Hyperthyroid on methimazole (21) | 91.5 ± 7.7 | 8.2 ± 8.0 | 0.3 ± 1.1 |
4.4. Changes in Body Weight
There was a 1.45 ± 3.65 and 0.3 ± 3.5 kg increase in the body weight in the short- and long-term groups, respectively (P = 0.017).
4.5. Adverse Events
During short-term MMI treatment, minor complications, such as cutaneous reactions, leukopenia, elevated liver enzymes, and arthralgia, occurred in 12% of patients. No case of major adverse events was observed. After one year of MMI therapy, there was no case of minor or major complications.
5. Discussion
The present study reports extended follow-up of thyroid status following short- and long-term continuous methimazole therapy. The results showed that those treated with long-term methimazole spent more time in euthyroidism during the 132-month post-randomization period.
Sustained normal levels of TSH during the post-treatment follow-up of patients with hyperthyroidism are an essential aspect of cardiovascular safety. All-cause mortality may increase in hyperthyroidism due to both nodular and diffuse toxic goiter (6). If thyrotoxicosis is not adequately corrected, it may be accompanied by an augmented risk of mortality, stroke, health failure, and cardiac arrhythmias (7). It has been reported that suppressed TSH for a long duration in both treated and untreated patients is associated with a rise in cardiovascular outcomes (8). Early and effective control of hyperthyroidism, regardless of treatment modality, is associated with better-improved survival than less effective control of the disease (7). Therefore, the main objective in managing patients with hyperthyroidism should focus on inducing rapid euthyroidism and its maintenance throughout management (7, 9).
It has been reported that after conventional 12 - 18 months of ATD treatment, 53% of patients with TRAb titers of normal or slightly elevated 0.9 - 4.4 IU/L at the end of therapy experience hyperthyroidism relapse after the cessation of ATD therapy (14). Fluctuating TRAb titers probably cause relapse in 30% - 40% of Graves’ patients during the first 5 - 6 years of ATD therapy (15, 16). Few studies have shown that remission rates after ATD treatment up to 42 months were not significantly different from ATD therapy for 12 - 24 months (17-20). Therefore, the length of long-term therapy for optimum TRAb suppression and the highest remission rate has been suggested at ≥60 months of treatment (5, 21).
The findings of the present study show that the time spent in euthyroidism during the years of continuous methimazole is longer when the original course of treatment is ≥60 months compared to a conventional shorter treatment period of 18 months. The difference is mainly due to the lower recurrence rate of hyperthyroid patients who have long-term compared to short-term methimazole treatment (18% vs. 50% in the percent study), among those who had a recurrence of thyrotoxicosis, treatment with additional courses of methimazole induced longer euthyroidism compared to patients who chose radioiodine treatment because most of such patients develop hypothyroidism and require life-long levothyroxine therapy. Considerable variability of serum TSH during levothyroxine treatment has been reported by many studies, causing periods of subclinical hyper- and hypothyroidism (22-24).
The strength of this study is that we aimed, designed, and performed the study to address a knowledge gap in the comparative effectiveness of short-term versus long-term methimazole treatment duration regarding the induction of sustained euthyroidism. The findings should aid decision-making in adapting the most appropriate therapy for patients with hyperthyroidism.
This study has some limitations. First, the survey was not double-blinded and may contain selection and assignment biases. The goiter size at the time of randomization was smaller in the long-term group than in the short-term group; however, thyroid function tests and TRAb values did not differ between the two groups. Second, the number of visits and frequency of laboratory assessments were limited; therefore, the exact time of sustained euthyroidism may be debatable. Third, patients' quality of life, as an essential outcome, was not studied in patients of the two groups.
5.1. Conclusions
Long-term methimazole therapy is accompanied by more sustainable normal serum TSH during long-term follow-up than short-term (conventional) methimazole therapy. This additional benefit, along with the cure of hyperthyroidism in approximately four-fifths of patients after an extended follow-up of 132 months, indicates the superiority of long-term versus conventional short-term methimazole treatment.
Acknowledgements
References
-
1.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 american thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-421. [PubMed ID: 27521067]. https://doi.org/10.1089/thy.2016.0229.
-
2.
Burch HB, Cooper DS. Management of graves disease: A review. JAMA. 2015;314(23):2544-54. [PubMed ID: 26670972]. https://doi.org/10.1001/jama.2015.16535.
-
3.
Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: A systematic review and meta-analysis. Thyroid. 2017;27(10):1223-31. [PubMed ID: 28699478]. https://doi.org/10.1089/thy.2016.0652.
-
4.
Malboosbaf R, Azizi F. Long-term treatment with antithyroid drugs: Efficacy and safety. Int J Endocrinol Metab. 2020;18(Suppl). https://doi.org/10.5812/ijem.101487.
-
5.
Azizi F, Amouzegar A, Tohidi M, Hedayati M, Khalili D, Cheraghi L, et al. Increased remission rates after long-term methimazole therapy in patients with graves' disease: Results of a randomized clinical trial. Thyroid. 2019;29(9):1192-200. [PubMed ID: 31310160]. https://doi.org/10.1089/thy.2019.0180.
-
6.
Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013;23(4):408-13. [PubMed ID: 23253072]. https://doi.org/10.1089/thy.2012.0500.
-
7.
Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, et al. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019;7(4):278-87. [PubMed ID: 30827829]. https://doi.org/10.1016/S2213-8587(19)30059-2.
-
8.
Lillevang-Johansen M, Abrahamsen B, Jorgensen HL, Brix TH, Hegedus L. Excess mortality in treated and untreated hyperthyroidism is related to cumulative periods of low serum TSH. J Clin Endocrinol Metab. 2017;102(7):2301-9. [PubMed ID: 28368540]. https://doi.org/10.1210/jc.2017-00166.
-
9.
Ganji SS, Cooper DS. Long-term methimazole is as effective as radioiodine therapy for the treatment of toxic multinodular goiter. Clinical Thyroidology. 2019;31(5):185-8. https://doi.org/10.1089/ct.2019;31.185-188.
-
10.
Azizi F. Long-term treatment of hyperthyroidism with antithyroid drugs: 35 years of personal clinical experience. Thyroid. 2020;30(10):1451-7. [PubMed ID: 32253999]. https://doi.org/10.1089/thy.2019.0814.
-
11.
Azizi F, Abdi H, Amouzegar A. Control of graves' hyperthyroidism with very long-term methimazole treatment: A clinical trial. BMC Endocr Disord. 2021;21(1):16. [PubMed ID: 33446181]. [PubMed Central ID: PMC7807686]. https://doi.org/10.1186/s12902-020-00670-w.
-
12.
Delshad H, Amouzegar A, Mirmiran P, Mehran L, Azizi F. Eighteen years of continuously sustained elimination of iodine deficiency in the Islamic Republic of Iran: the vitality of periodic monitoring. Thyroid. 2012;22(4):415-21. [PubMed ID: 22409203]. https://doi.org/10.1089/thy.2011.0156.
-
13.
Amouzegar A, Delshad H, Mehran L, Tohidi M, Khafaji F, Azizi F. Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: a population based study. J Endocrinol Invest. 2013;36(11):950-4. [PubMed ID: 23873252]. https://doi.org/10.3275/9033.
-
14.
Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, et al. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. Thyroid. 2006;16(3):295-302. [PubMed ID: 16571093]. https://doi.org/10.1089/thy.2006.16.295.
-
15.
Okamura K, Bandai S, Fujikawa M, Sato K, Ikenoue H, Kitazono T. Long-term antithyroid drug treatment: Trends in serum TSH and TSH receptor antibody changes in patients with graves’ disease. Int J Endocrinol Metab. 2020;18(Suppl). https://doi.org/10.5812/ijem.101139.
-
16.
Villagelin D, Santos RB, Romaldini JH. Remission rate of graves' disease and the trend of changes in serum TSH receptor antibodies in prolonged antithyroid drug treatment. Int J Endocrinol Metab. 2020;18(Suppl). https://doi.org/10.5812/ijem.101473.
-
17.
Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, et al. Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. Endocr J. 2011;58(2):95-100. [PubMed ID: 21206137]. https://doi.org/10.1507/endocrj.k10e-262.
-
18.
Maugendre D, Gatel A, Campion L, Massart C, Guilhem I, Lorcy Y, et al. Antithyroid drugs and graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf). 1999;50(1):127-32. [PubMed ID: 10341866]. https://doi.org/10.1046/j.1365-2265.1999.00629.x.
-
19.
Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest. 2008;31(10):866-72. [PubMed ID: 19092290]. https://doi.org/10.1007/BF03346433.
-
20.
Shizume K, Irie M, Nagataki S, Matsuzaki F, Shishiba Y. Long-term result of antithyroid drug therapy for Grave's disease: follow up after more than 5 years. Endocrinol Jpn. 1970;17(5):327-32. [PubMed ID: 4101380]. https://doi.org/10.1507/endocrj1954.17.327.
-
21.
Azizi F, Abdi H, Mehran L, Amouzegar A. Appropriate duration of antithyroid drug treatment as a predictor for relapse of Graves' disease: a systematic scoping review. J Endocrinol Invest. 2022;45(6):1139-50. [PubMed ID: 35088381]. https://doi.org/10.1007/s40618-021-01730-1.
-
22.
Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695-701. [PubMed ID: 15879354]. https://doi.org/10.1530/eje.1.01904.
-
23.
Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y. Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. Arch Iran Med. 2012;15(8):477-84. [PubMed ID: 22827783].
-
24.
Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160(4):526-34. [PubMed ID: 10695693]. https://doi.org/10.1001/archinte.160.4.526.